Moderna Inc. announced its plans to develop more mRNA vaccines for the 15 most dangerous infectious diseases after its reported total revenue of $18.5 billion for the full year of 2021 due to its Covid-19 vaccine.
Moderna launched a new program called mRNA Access that will allow researchers to use its mRNA technology to research new vaccines against emerging or neglected infectious diseases.
The 15 pathogens that Moderna is planning to develop mRNA vaccines include Chikungunya virus, COVID-19, Crimean-Congo hemorrhagic fever, Dengue, Ebola virus disease, HIV, Malaria, Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV), Nipah and henipaviral diseases, Rift Valley fever, Severe fever with Thrombocytopenia Syndrome, Tuberculosis, Zika.
The clinical trials are expected to start in 2025.
According to their news release, “Moderna also announced that with the assistance of the U.S. government, it has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish Kenya as the location for its mRNA manufacturing facility.”
Read their news release here and below:
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its global public health strategy through four new initiatives aimed at advancing mRNA vaccines for the prevention of infectious diseases.
First, Moderna is announcing a commitment to expand its global public health portfolio to 15 vaccine programs targeting priority pathogens that threaten global health, advancing these vaccines into clinical studies by 2025.
Second, to accelerate research with the aim of advancing additional vaccines, Moderna is launching a new program, mRNA Access that will offer researchers use of Moderna’s mRNA technology to explore new vaccines against emerging or neglected infectious disease.
Third, Moderna is expanding its patent pledge to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income countries.
Fourth, Moderna announced that with the assistance of the U.S. government, it has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish Kenya as the location for its mRNA manufacturing facility.
The World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) have issued calls to action to develop vaccines against priority pathogens that pose a threat to public health. Moderna’s clinical portfolio already includes vaccines targeting COVID-19, HIV, Nipah and Zika. Moderna’s expanded global health strategy will advance programs against the remaining pathogens by 2025. Moderna is also continuing its prototype vaccine approach, using preliminary versions of vaccines developed against representative viruses, which are rapidly adapted to tackle other related pathogens, in this way, preparing for Disease X. The value of this prototype vaccine approach was demonstrated when early research on SARS-CoV-1 and MERS enabled Moderna’s rapid response to SARS-CoV-2. Moderna is committing, in part through mRNA Access, to continue research and early development toward pandemic preparedness through a prototype pathogen approach to creating vaccine libraries.
“Despite the rapid development timelines of our COVID-19 vaccine, and substantial efforts undertaken to scale up our manufacturing, the human toll of COVID-19 has been devastating and we must not assume that the COVID-19 pandemic will be the last pandemic that will impact global health. We are dedicated to pursuing innovative vaccine solutions to address infectious diseases that pose the greatest risk to public health through collaborative research and development,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Since our beginning, we have focused on developing a global health vaccine program and today, we are renewing that focus by expanding our work to develop vaccines against priority pathogens that threaten global health and by launching our new mRNA Access program to create a community of global scientists to access our mRNA vaccine technology from anywhere in the world. At Moderna, we believe the world needs novel, innovative approaches to address both known and emerging infectious diseases and we know that we can’t go it alone. We are committed to bringing the full force of our mRNA vaccine platform to combat infectious diseases of public health concern and we look forward working with global partners to be part of the solution to prevent future pandemics and help millions of people around the world.”
Read the rest here.